Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for statin
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Impact of statin therapy on coronary plaque burden and composition assessed by coronary computed tomographic angiography: a systematic review and meta-analysis. To clarify the potential role of coronary computed tomographic angiography (CCTA) in assessing the remodelling impact of statin therapy on plaque burden and compositions.A systematic literature review and meta-analysis were conducted to examine the effect of statin therapy on different plaque volumes assessed by serial CCTA. Twelve (...) studies were included with a mean (±standard deviation) follow-up period of 14.5 ± 9.5 months. Data on plaque volume were pooled using weighted mean difference method. Available data on a total of 199 intensive statin therapy receivers, 404 moderate statin therapy receivers and 189 controls (mean age = 62 ± 5 years, male gender = 78%) were meta-analysed. Intensive statin therapy reduced total plaque volume (TPV) by -20.87 [95% confidence interval (CI) -31.17, -10.56; P < 0.001] mm3, while moderate
Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. Statins may prevent recurrent ischemic events after ischemic stroke. Determining which statin to use remains controversial. We aimed to summarize the evidence for the use of statins in secondary prevention for patients with ischemic stroke by comparing benefits and harms of various statins.We searched for randomized controlled trials (RCTs (...) ) assessing statins in patients with ischemic stroke or transient ischemic attack (TIA) in MEDLINE, EMBASE, and CENTRAL up to July 2017. Two authors extracted data and appraised risks of bias. We performed pairwise meta-analyses and trial sequential analyses (TSA) to compare statins versus placebo/no statin, and network meta-analyses using frequentist random-effects models to compare statins through indirect evidence. We used GRADE to rate the overall certainty of evidence. Primary outcomes were all-cause
the risk of developing cataracts in patients treated with statins. A meta-analysis was performed to estimate odds ratios (ORs). Results were stratified according to the following studies' subgroups: design, methodological quality, method of diagnosis of cataract, patients' age, and median follow-up. Meta-regressions evaluated the influence of the following risk factors: smoking, hypertension, corticosteroids, selective serotonin reuptake inhibitors (SSRI), diabetes mellitus, and cardiovascular (...) Statins and risk of cataracts: A systematic review and meta-analysis of observational studies. Two previous meta-analyses evaluated the risk of cataracts associated with statins, but did not include relevant studies suggesting a cataractogenic effect.The aim of this systematic review and meta-analysis of observational studies is to evaluate such association considering the latest published evidence.A literature search was conducted to identify observational, comparative studies evaluating
Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Numerous studies have illustrated the relationship between SLCO1B1 T521C polymorphism and statin-induced myopathy risk; however, this association is not consistent. Three electronic databases (PubMed, EMBASE, and the Cochrane Library) were searched from inception to October 2017 to identify potential studies. The summary odds ratios (ORs) with 95% confidence intervals (CIs) were calculated from (...) different genetic models by using a random-effects model. Fourteen studies comprising 3265 myopathy patients and 7743 controls were included. The summary ORs suggested that 521CC (OR: 2.31; 95% CI: 1.15-4.63; P = 0.019), 521TC (OR: 1.34; 95% CI: 1.02-1.76; P = 0.034), and 521CC + TC (OR: 1.82; 95% CI: 1.32-2.51; P < 0.001) were associated with a greater risk of statin-induced myopathy than 521TT. The higher incidence of statin-induced myopathy was found to be significantly correlated with the C allele
England Mayo Clin Proc 0405543 0025-6196 0 Hydroxymethylglutaryl-CoAReductaseInhibitors AIM IM Mayo Clin Proc. 2018 Jul;93(7):960 29933943 Coronary Disease prevention & control Databases, Factual Drug Prescriptions statistics & numerical data Humans Hydroxymethylglutaryl-CoAReductaseInhibitors therapeutic use Medication Adherence statistics & numerical data Patient Compliance statistics & numerical data Time Factors Treatment Refusal statistics & numerical data 2017 10 20 2018 01 09 2018 5 6 6 0 (...) Reinitiation of Statin Therapy After Discontinuation: A Meta-analysis. 29728206 2019 03 12 2019 03 12 1942-5546 93 5 2018 05 Mayo Clinic proceedings Mayo Clin. Proc. Reinitiation of Statin Therapy After Discontinuation: A Meta-analysis. 666-668 S0025-6196(18)30041-7 10.1016/j.mayocp.2018.01.011 Ofori-Asenso Richard R Monash University, Melbourne, Australia. Zoungas Sophia S Monash University, Melbourne, Australia. Liew Danny D Monash University, Melbourne, Australia. eng Letter Meta-Analysis
Statins do not increase risk of polyneuropathy: A case-control study and literature review To investigate whether there is an association between cholesterol-lowering medication use, specifically statins, and chronic polyneuropathy.A literature study was carried out to assess the current state of evidence on the association between chronic polyneuropathy and cholesterol-lowering medication use. We also conducted a prospective case-control study to compare exposure to cholesterol-lowering (...) . There was insufficient evidence that statin use is a risk factor for polyneuropathy. Our prospective case-control study included 333 patients with cryptogenic axonal polyneuropathy and 283 controls. Patients with polyneuropathy were less likely to have been exposed to statins than controls (OR 0.56, 95% confidence interval 0.34-0.95, p = 0.03). The odds of polyneuropathy decreased as exposure duration to statins increased. Cholesterol-lowering medication consisted almost exclusively of statins; therefore we only
Effect of statins on Parkinson's disease: A systematic review and meta-analysis. Statins have key lipid-lowering, anti-inflammatory, and anti-oxidative effects. However, it remains unclear whether statins are beneficial to patients with Parkinson's disease (PD). This study aimed to evaluate the relationship between statins and PD through a systematic review.This study adhered to the guideline of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Potentially relevant (...) patients; 8 case-control and 9 cohort studies), including 5 articles not cited by other studies. We searched the Chinese database, but unfortunately, no Chinese literature can be included in the study. Briefly, statins could decrease the risk of PD, with a summary OR of 0.92 (95% CI: 0.86-0.99). A sensitivity analysis demonstrated the robustness of the results. Subgroup analyses revealed heterogeneity across the studies in terms of subject race, study type, reporting style, quality, statins type
Do adjunctive statins improve periodontal treatment outcomes in patients with chronic periodontitis? Data sources Medline-PubMed, Scopus and Embase databases.Study selection Controlled clinical trials studies with at least one month follow-up that utilised locally or systemically delivered statins as a sole adjunctive treatment to mechanical periodontal therapy in patients diagnosed with chronic or aggressive periodontitis were included. Selection was carried out independently by two reviewers (...) in the systematic review, with ten investigations included in the meta-analysis. In the meta-regression, the additional use of simvastatin, rosuvastatin and atorvastatin decreased pocket depth in contrast with mechanical periodontal treatment and a placebo gel (p < 0.05). Simvastatin and rosuvastatin significantly reduced the development of intrabony defect in contrast with control group (p < 0.05). Statins failed to provide a statistically significant difference between the adjunct therapy for both periodontal
Association between statin use and herpes zoster: systematic review and meta-analysis. Statins are commonly prescribed worldwide. In addition to being potent lipid-lowering agents, statins have immunomodulating properties that may increase the risk of varicella zoster virus reactivation. This adverse effect may have substantial public health implications.We performed a meta-analysis of observational studies to assess the association between statin use and the risk of herpes zoster infection. We (...) searched PubMed, Embase, Web of Science and Cochrane databases to identify studies published from 1980 to 2018. The multivariate-adjusted ORs were pooled using random-effect models, and subgroup and sensitivity analyses were performed to examine the source of heterogeneity.Six studies were analysed, with a total of more than two million participants. We determined if the use of statins might increase the risk of infection of herpes zoster (OR 1.18, 95% CI 1.11 to 1. 25). We detected significant
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large statin trials to compare the effects of statin therapy at different ages.In this meta-analysis, randomised trials (...) of statin therapy were eligible if they aimed to recruit at least 1000 participants with a scheduled treatment duration of at least 2 years. We analysed individual participant data from 22 trials (n=134 537) and detailed summary data from one trial (n=12 705) of statin therapy versus control, plus individual participant data from five trials of more intensive versus less intensive statin therapy (n=39 612). We subdivided participants into six age groups (55 years or younger, 56-60 years, 61-65 years, 66
Locally applied statins as adjuvants to non-surgical periodontal treatment for chronic periodontitis: a systematic review and meta-analysis. This review aimed at evaluating the effects of chronic periodontitis (CP) treatment with local statins as adjuncts to scaling and root planing (SRP), compared with SRP alone or with placebo.Electronic and hand searches were conducted in three databases to select randomized controlled trials (RCTs) comparing SRP + statins versus SRP alone. Random effects (...) ] = 1.45 to 2.23; p = 0.000), PPD reduction (MD = 1.69 mm, 95% CI = 1.37 to 2.04; p = 0.000), mSBI change (MD = 0.70, 95% CI = 0.57 to 0.84; p = 0.000), and IBD (MD = 1.48, 95% CI = 1.30 to 1.67; p = 0.000) attributed to SRP + statin treatment (6 months).Within the limitations of this study, the collective evidence emerging from this systematic review and meta-analysis may support the use of locally applied statins as adjuncts to SRP in CP treatment, based on being an easy, low-cost alternative
Effectiveness of long-term using statins in COPD - a network meta-analysis. To evaluate the effectiveness of long-term treatment of statins for chronic obstructive pulmonary disease (COPD), and to answer which one is better.General meta-analysis was performed to produce polled estimates of the effect of mortality, inflammatory factors, and lung function index in COPD patients by the search of PubMed, Web of Science, Embase, and China National Knowledge Infrastructure for eligible studies (...) . A network meta-analysis was performed to synthetically compare the effectiveness of using different statins in COPD patients.General meta-analysis showed that using statins reduced the risk of all-cause mortality, heart disease-related mortality and COPD acute exacerbation (AECOPD) in COPD patients, the RR (95% CI) were 0.72 (0.63,0.84), 0.72 (0.53,0.98) and 0.84 (0.79,0.89), respectively. And using statins reduced C-reactive protein (CRP) and pulmonary hypertension (PH) in COPD patients, the SMD (95
Association of statin pretreatment with collateral circulation and final infarct volume in acute ischemic stroke patients: A meta-analysis. Statin pretreatment (SP) is associated with improved outcomes in acute ischemic stroke (AIS) patients. Collateral circulation status and final infarct volume (FIV) are independent predictors of functional outcome in AIS.We sought to evaluate the association of SP with collateral circulation and FIV in AIS patients. We used a random-effects model for all
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. The current guidelines of statins for primary cardiovascular disease (CVD) prevention were based on results from systematic reviews and meta-analyses that suffer from limitations.We searched in PubMed for existing systematic reviews and individual open (...) -label or double-blinded randomized controlled trials that compared a statin with a placebo or another, which were published in English until January 01, 2018. We performed a random-effect pairwise meta-analysis of all statins as a class and network meta-analysis for the specific statins on different benefit and harm outcomes.In the pairwise meta-analyses, statins as a class showed statistically significant risk reductions on non-fatal MI (risk ratio [RR] 0.62, 95% CI 0.53-0.72), CVD mortality (RR
A, Taylor HL, Blackburn H, et al. Coronary Heart Disease among Minnesota Business and Professional Men Followed Fifteen Years. Circulation 28:381-95 (Sept 1963) 9. Tobert JA. Lovastatin and beyond: the history of the HMG-CoAreductaseinhibitors. Nat Rev Drug Discov. 2003;2(7):517-26. 10. Peter Landers. How one scientist intrigued by molds found first statin. Wall Street Journal. January 9, 2006. 11. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced (...) in August 1987. Although the main mechanism of statins to inhibit HMG-CoAreductase was understood, it was not until the work of Drs. Brown and Goldstein in the 1970’s that allowed us to fully comprehend how this class of medication lowers cholesterol. Working with tissue samples from people afflicted with familial hypercholesterolemia, Brown and Goldstein elucidated the cell-surface LDL receptor and demonstrated that inhibition of HMG-CoAreductase stimulates the upregulation of hepatic LDL receptors
HISTORICAL AND CURRENT STATIN USE IN BELGIUM 3.1 Introduction Statins (also known as HMG-CoAreductaseinhibitors) are a class of lipid- lowering medications. Statins proved to reduce the relative risk for cardiovascular disease (CVD), CVD events and mortality similarly in all individuals, but the absolute risk reduction is much greater in those who are at high risk of CVD events. Statins are used both in the primary and secondary prevention of CVD. Clinical practice guidelines generally recommend (...) the full responsibility of the KCE. Publication date: 15 January 2019 Domain: Health Technology Assessment (HTA) MeSH: Hydroxymethylglutaryl-CoAReductaseInhibitors; Cardiovascular Diseases; Primary prevention; Costs and Cost Analysis. NLM Classification: WG 120 Language: English Format: Adobe® PDF™ (A4) Legal depot: D/2019/10.273/07 ISSN: 2466-6459 Copyright: KCE reports are published under a “by/nc/nd” Creative Commons Licence http://kce.fgov.be/content/about-copyrights-for-kce-publications. How
of these events is a priority. Overall, in patients for whom statin treatment is recommended by current guidelines, the benefits greatly outweigh the risks. The development and use of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductaseinhibitor (statin) class of drugs, which, according to the prescribing information, reduce low-density lipoprotein cholesterol (LDL-C) on average by 55% to 60% at the maximal doses of the most potent statins, has had a major impact in reducing the incidence (...) metabolites, which is equivalent to taking a larger dose, and thereby increases the risk of myopathy/rhabdomyolysis. The most important pharmacokinetic difference among the statins is that only lovastatin, simvastatin, and atorvastatin are cytochrome P450 3A4 (CYP3A4) substrates and consequently are vulnerable to drug interactions with CYP3A4 inhibitors, some of which are commonly used. Because of the high first-pass metabolism of lovastatin and simvastatin, the effects of CYP3A4 inhibitors
Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. Previous research has shown that statin adherence for the primary prevention of CVD is lower compared to secondary prevention populations. Therefore the aim of this systematic review was to review predictors of statin adherence for the primary prevention of CVD.A systematic search of papers published between Jan 1984 and May 2017 was conducted in PubMed, PsycINFO, EMbase and CINAHL (...) databases. A study was eligible for inclusion if; 1) it was a study of the general population or of patients with familial hypercholesterolemia, hypertension, diabetes or arthritis; 2) statins were prescribed; 3) adherence was defined and measured as the extent to which patients followed their statin regimen during the period of prescription, and 4) it was an original trial or observational study (excluding case reports). A study was subsequently excluded if 1) results were not presented separately
Formal comment on "Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease". Statins have been prescribed for primary prevention of cardiovascular disease (CVD) for nearly 3 decades. Throughout this period key opinion leaders in the field have been dismayed by the high rate of non-adherence of patients to follow their statin regimen. Hope et al.,  have addressed this issue by providing a systematic review of research on predictors (...) of statin adherence for primary prevention of CVD. However, their review does not address the ongoing debate as to whether statin treatment is warranted for primary prevention of CVD, nor does it adequately address concerns regarding adverse effects of statins. We have therefore written a commentary which provides a broader perspective on the benefits versus harms of statin therapy. Our perspective of the literature is that non-adherence to statin treatment for primary prevention of CVD is justified